Quality by design (QbD) approach to formulate in situ gelling system for nose to brain delivery of Fluoxetine hydrochloride: Ex-vivo and In-vivo study
DOI:
https://doi.org/10.30827/ars.v58i3.6528Keywords:
Nasal, Fluoxetine hydrochloride, PharmacodynamicAbstract
Objective: The purpose of the present study is to develop an ion sensitive in situ nasal gel of Fluoxetine hydrochloride for brain delivery. A 32 factorial design was used to investigate effect of independent variable on dependent variables.
Methods: Formulations were evaluated for gelation study, viscosity, gel strength, mucoadhesion strength, drug content, ex-vivo drug permeation, in vivo pharmacodynamic and stability study.
Results: The results revealed that as the concentration of gellan gum and HPMC were increased, there was increase in viscosity and mucoadhesive strength and decrease in percent release. The optimized formulation F4 showed highest drug release 94.24 %. In locomotor activity and forced swim test study, the in situ gel treated rats showed significant responses as compared to control group. Histopathological examinations showed no evidence of nasal mucosal damage. The in situ nasal gel was stable after 3 months.
Conclusion: It was concluded that, the in situ nasal formulations of Fluoxetine hydrochloride which enhanced nasal absorption and patient compliance for the treatment of depression.
Downloads
References
Tortora GJ, Derrickson B. Principles of Anatomy and Physiology.; 2014. doi:10.1016/S0031-9406(05)60992-3.
Brunton L. Goodman & Gilman ’ S The Pharmacological Basis of Therapeutics.; 2006.
Belgamwar VS, Chauk DS, Mahajan HS, Jain SA, Gattani SG, Surana SJ. Formulation and evaluation of in situ gelling system of dimenhydrinate for nasal administration. Pharm Dev Technol. 2009;14(3):240-248. doi:10.1080/10837450802498910.
Kumar M, Pathak K, Misra A. Formulation and characterization of nanoemulsion-based drug delivery system of risperidone. Drug Dev Ind Pharm. 2009;35(4):387-395. doi:10.1080/03639040802363704.
Pardeshi CV, Belgamwar VS. Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting. Expert Opin Drug Deliv. 2013;10(7):957-972. doi:10.1517/17425247.2013.790887.
Astic L, Saucier D, Coulon P, Lafay F, Flamand A. The CVS strain of rabies virus as transneuronal tracer in the olfactory system of mice. Brain Res. 1993;619(1-2):146-156. doi:10.1016/0006-8993(93)91606-S.
Hussain A, Foster T, Hirai S, Kashihara T, Batenhorst R, Jones M. Nasal absorption of propranolol in humans. Sect Title Pharmacodyn. 1980;69(10):1240.
Pathan IB, Nirkhe SR, Bairagi A. In situ gel based on gellan gum as new carrier for nasal to brain delivery of venlafaxine hydrochloride : In vitro evaluation and in vivo study. J. Chem. Pharm. Res., 015;7(9):324-331.
Rozier A, Mazuel C, Grove J, Plazonnet B. Functionality testing of gellan gum, a polymeric excipient material for ophthalmic dosage forms. Int J Pharm. 1997;153(2):191-198. doi:10.1016/S0378-5173(97)00109-9.
Benfield P, Heel RC, Lewis SP. Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs. 1986;32(6):481-508. doi:10.2165/00003495-198632060-00002.
Fichtner CG, Braun BG. Hyperphagia and weight loss during fluoxetine treatment. Ann Pharmacother. 1994;28(12):1350-1352.
Reynolds, J.E.F., Prasad AB (eds. . Martindale-The Extra Pharmacopoeia. 28th ed. London: The Pharmaceutical Press, 1982., p. 61. Martindale-The Extra Pharmacopoeia.
Wernicke JF. Safety and side effect profile of fluoxetine. Expert Opin Drug Saf. 2004;3(5):495-504. doi:10.1517/14740338.3.5.495.
Altamura AC, Moro AR, Percudani M. Clinical Pharmacokinetics of Fluoxetine. Clin Pharmacokinet. 1994;26(3):201-214. doi:10.2165/00003088-199426030-00004.
Alderman CP, Seshadri P, Ben-Tovim DI. Effects of serotonin reuptake inhibitors on hemostasis. Ann Pharmacother. 1996;30(11):1232-1234. http://www.ncbi.nlm.nih.gov/pubmed/8913401.
Pathan IB, Chudiwal V, Farooqui I, Shingare P. Formulation design and evaluation of nasal in situ gel as a novel vehicle for Azelastine hydrochloride. Int J Drug Deliv. 2013;5(3):284-290.
Galgatte UC, Kumbhar AB, Chaudhari PD. Development of in situ gel for nasal delivery: design, optimization, in vitro and in vivo evaluation. Drug Deliv. 2014;21(1):62-73. doi:10.3109/10717544.2013.849778.
Chang JY, Oh YK, Choi H gon, Kim YB, Kim CK. Rheological evaluation of thermosensitive and mucoadhesive vaginal gels in physiological conditions. Int J Pharm. 2002;241(1):155-163. doi:10.1016/S0378-5173(02)00232-6.
Kim CK, Lee SW, Choi HG, et al. Trials of in situ-gelling and mucoadhesive acetaminophen liquid suppository in human subjects. Int J Pharm. 1998;174(1-2):201-207. doi:10.1016/S0378-5173(98)00258-0.
Bansal K, Rawat MK, Jain a, Rajput a, Chaturvedi TP, Singh S. Development of satranidazole mucoadhesive gel for the treatment of periodontitis. AAPS PharmSciTech. 2009;10(3):716-723. doi:10.1208/s12249-009-9260-z.
Naik A, Nair H. Formulation and evaluation of thermosensitive biogels for nose to brain delivery of doxepin. Biomed Res Int. 2014;2014. doi:10.1155/2014/847547.
Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15(1):25-35. doi:10.1016/0378-5173(83)90064-9.
Ali MS, Alam MS, Alam N, Anwer T, Safhi MMA. Accelerated stability testing of a clobetasol propionate-loaded nanoemulsion as per ICH guidelines. Sci Pharm. 2013;81(4):1089-1100. doi:10.3797/scipharm.1210-02.
Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn thérapie. 1977;229(2):327-336. doi:10.1196/annals.1317.038.
Paulus MP, Dulawa SC, Ralph RJ, Geyer MA. Behavioral organization is independent of locomotor activity in 129 and C57 mouse strains. In: Brain Research. Vol 835. ; 1999:27-36. doi:10.1016/S0006-8993(99)01137-3.
Bhandwalkar MJ, Avachat AM. Thermoreversible Nasal In situ Gel of Venlafaxine Hydrochloride: Formulation, Characterization, and Pharmacodynamic Evaluation. AAPS PharmSciTech. 2012;14(1):101-110. doi:10.1208/s12249-012-9893-1.
Andrews GP, Laverty TP, Jones DS. Mucoadhesive polymeric platforms for controlled drug delivery. Eur J Pharm Biopharm. 2009;71(3):505-518. doi:10.1016/j.ejpb.2008.09.028.
Jaipal A, Pandey MM, Abhishek A, Vinay S, Charde SY. Interaction of calcium sulfate with xanthan gum: Effect on in vitro bioadhesion and drug release behavior from xanthan gum based buccal discs of buspirone. Colloids Surfaces B Biointerfaces. 2013;111:644-650. doi:10.1016/j.colsurfb.2013.06.052.
Nickerson MT, Paulson a. T. Rheological properties of gellan, kappa-carrageenan and alginate polysaccharides: Effect of potassium and calcium ions on macrostructure assemblages. Carbohydr Polym. 2004;58(1):15-24. doi:10.1016/j.carbpol.2004.06.016.
Downloads
Published
How to Cite
Issue
Section
License
The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:
- The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.
b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.
c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).
